SCHEMBL5620271

SCHEMBL5620271

O=C(O)NCc1cc(C(F)(F)F)ccc1F

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
USP30 Q70CQ3 1/20 0.51
KMT2A Q03164 3/20 0.48
IDO1 P14902 1/20 0.47
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
PPARA Q07869 1/20 0.47
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
DDR1 Q08345 2/20 0.44
RIPK1 Q13546 7/20 0.44
FPR3 P25089 1/20 0.43
FPR2 P25090 1/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
EPHX2 P34913 1/20 0.42
NR1H4 Q96RI1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5208250 0.86 POLB (0.50) POLBUSP30KMT2AIDO1PPARG
SCHEMBL1483170 0.83 POLB (0.48) POLBUSP30KMT2AIDO1PPARG
SCHEMBL11362695 0.83 POLB (0.48) POLBUSP30KMT2AIDO1LMNA
SCHEMBL5144626 0.83 P2RX7 (0.55) KMT2ALMNAL3MBTL1FPR3FPR2
SCHEMBL5968616 0.81 MPO (0.43) LMNAEPHX2NR1H4
SCHEMBL27931784 0.80 L3MBTL1 (0.52) POLBUSP30KMT2ALMNANPSR1
SCHEMBL5513992 0.80 KMT2A (0.46) POLBUSP30KMT2AIDO1PPARG
SCHEMBL582826 0.80 KMT2A (0.46) POLBUSP30KMT2AIDO1PPARG
SCHEMBL27669390 0.80 KMT2A (0.46) POLBUSP30KMT2AIDO1PPARG
SCHEMBL5517353 0.80 KMT2A (0.46) POLBUSP30KMT2AIDO1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166587-B2 Carbamic acid alkyl ester derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-23 US claimed
US-20050075327-A1 Carbamic acid alkyl ester derivatives HOFFMAN-LA ROCHE INC. 2005-04-07 US claimed
EP-1673347-B1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-19 EP disclosed
US-7166587-B2 Carbamic acid alkyl ester derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-23 US disclosed
EP-1673347-A1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS F. Hoffman-la Roche AG (CH) 2006-06-28 EP disclosed
WO-2005040126-A1 SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USEFUL AS GAMMA-SECRETASE INHIBITORS F. HOFFMAN-LA ROCHE AG (CH) 2005-05-06 WO disclosed
US-20050075327-A1 Carbamic acid alkyl ester derivatives HOFFMAN-LA ROCHE INC. 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075327-A1 Carbamic acid alkyl ester derivatives BCHE, CHRM1, ADCY7 POLB 3946/4885USP30 1296/4885KMT2A 2212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.